TOR1A and type 1 diabetes mellitus: In contrast, Bakker et al34 reported that HLA‐DQ2.5 homozygosity is expected in 30% of the T1D w/CD group, indicating that a double dose of DQ2.5 confers the highest risk for T1D patients to develop CD as shown previously.35